Unicycive Therapeutics (UNCY) Earnings Analysis
Unicycive Therapeutics (UNCY) next reports earnings on 2026-08-13, consensus EPS -0.471 USD. Last quarter (2026-03-30) it beat with EPS -0.32 USD vs -0.50465 USD est (+36.6%). It has beaten estimates in 4/5 recent quarters (80%). Trailing P/E -2.72.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does UNCY next report earnings?
| Next earnings date | 2026-08-13 |
|---|---|
| Consensus EPS estimate | -0.471 USD |
| Revenue estimate | 0.02B |
UNCY earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-03-30 | -0.32 USD | -0.50465 USD | +36.6% | Beat |
| 2025-11-12 | -0.39 USD | -0.59 USD | +33.9% | Beat |
| 2025-08-14 | -0.52 USD | -0.7 USD | +25.7% | Beat |
| 2025-03-31 | -0.26 USD | -0.13 USD | -100% | Miss |
| 2024-08-14 | -0.15 USD | -0.23 USD | +34.8% | Beat |
Beat rate: 4/5 (80%) over reported quarters with consensus data.
UNCY valuation and analyst view
| Trailing P/E | -2.72 |
|---|---|
| Trailing EPS | -0.16709 USD |
| Price / book | 35.32 |
| Dividend yield | 0.00% |
| Market cap | 0.12B |
| Analyst consensus | Buy (8 buy / 0 hold / 0 sell) |
| Avg price target | 22 USD |
Related research pages
Frequently asked questions
When is Unicycive Therapeutics (UNCY)'s next earnings date?
Unicycive Therapeutics is next scheduled to report on 2026-08-13, with a consensus EPS estimate of -0.471 USD and revenue estimate of 0.02B.
Did UNCY beat earnings last quarter?
In its 2026-03-30 report, UNCY posted EPS of -0.32 USD versus a -0.50465 USD estimate — a beat of 36.6%.
What is UNCY's earnings track record?
Over the last 5 reported quarters with consensus data, UNCY beat estimates 4 times (80%).
What is UNCY's current P/E ratio and EPS?
UNCY trades at a trailing P/E of -2.72 on trailing EPS of -0.16709362701501868 USD.
What do analysts rate UNCY?
Analyst consensus is "Buy" across 8 ratings (0 strong buy, 8 buy, 0 hold, 0 sell, 0 strong sell). Average 12-month price target: 22 USD.